JP2021515597A5 - - Google Patents
Info
- Publication number
- JP2021515597A5 JP2021515597A5 JP2020570410A JP2020570410A JP2021515597A5 JP 2021515597 A5 JP2021515597 A5 JP 2021515597A5 JP 2020570410 A JP2020570410 A JP 2020570410A JP 2020570410 A JP2020570410 A JP 2020570410A JP 2021515597 A5 JP2021515597 A5 JP 2021515597A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- sequence number
- spik
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127022A JP7539536B2 (ja) | 2018-03-06 | 2023-08-03 | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639345P | 2018-03-06 | 2018-03-06 | |
| US62/639,345 | 2018-03-06 | ||
| US201862639850P | 2018-03-07 | 2018-03-07 | |
| US62/639,850 | 2018-03-07 | ||
| PCT/US2019/020999 WO2019173503A2 (en) | 2018-03-06 | 2019-03-06 | Serine protease inhibitor kazal (spik) compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127022A Division JP7539536B2 (ja) | 2018-03-06 | 2023-08-03 | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515597A JP2021515597A (ja) | 2021-06-24 |
| JP2021515597A5 true JP2021515597A5 (https=) | 2022-03-15 |
| JP7328261B2 JP7328261B2 (ja) | 2023-08-16 |
Family
ID=65818672
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570410A Active JP7328261B2 (ja) | 2018-03-06 | 2019-03-06 | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 |
| JP2023127022A Active JP7539536B2 (ja) | 2018-03-06 | 2023-08-03 | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127022A Active JP7539536B2 (ja) | 2018-03-06 | 2023-08-03 | セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12180301B2 (https=) |
| EP (1) | EP3762426A2 (https=) |
| JP (2) | JP7328261B2 (https=) |
| CN (2) | CN120005029A (https=) |
| CA (1) | CA3093295A1 (https=) |
| WO (1) | WO2019173503A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12180301B2 (en) | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
| US12377162B2 (en) | 2019-07-08 | 2025-08-05 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use |
| EP4028132A1 (en) | 2019-09-11 | 2022-07-20 | Imcare Biotech, LLC | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies |
| JP2023542867A (ja) | 2020-09-11 | 2023-10-12 | グリンプス バイオ， インコーポレイテッド | 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6248564B1 (en) | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| CA2467242A1 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US8193328B2 (en) * | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
| CA2703140A1 (en) | 2007-10-25 | 2009-04-30 | Viventia Biotech Inc. | Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| WO2011102999A2 (en) * | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Spink1 targeted therapy |
| WO2012078752A2 (en) | 2010-12-09 | 2012-06-14 | Philadelphia Health & Education Corporation D/B/A | Serine protease inhibitor kazal antibodies |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| CA2898472C (en) | 2013-02-15 | 2023-03-07 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| EA202091540A1 (ru) * | 2017-12-22 | 2021-03-22 | Джаунс Терапьютикс, Инк. | Антитела к lilrb2 |
| US12180301B2 (en) | 2018-03-06 | 2024-12-31 | Imcare Biotech, Llc | Serine protease inhibitor kazal (SPIK) compositions and methods |
| CN109776679B (zh) * | 2019-01-08 | 2022-06-17 | 灏灵赛奥（天津）生物科技有限公司 | 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用 |
| CN109678950B (zh) | 2019-01-08 | 2022-05-10 | 灏灵赛奥（天津）生物科技有限公司 | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 |
| US12377162B2 (en) | 2019-07-08 | 2025-08-05 | Imcare Biotech, Llc | Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use |
| JP7713956B2 (ja) * | 2020-04-15 | 2025-07-28 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
-
2019
- 2019-03-06 US US16/978,634 patent/US12180301B2/en active Active
- 2019-03-06 CN CN202510180099.6A patent/CN120005029A/zh active Pending
- 2019-03-06 WO PCT/US2019/020999 patent/WO2019173503A2/en not_active Ceased
- 2019-03-06 CA CA3093295A patent/CA3093295A1/en active Pending
- 2019-03-06 CN CN201980017414.6A patent/CN112292401A/zh active Pending
- 2019-03-06 JP JP2020570410A patent/JP7328261B2/ja active Active
- 2019-03-06 EP EP19712403.5A patent/EP3762426A2/en active Pending
-
2023
- 2023-08-03 JP JP2023127022A patent/JP7539536B2/ja active Active
-
2024
- 2024-11-20 US US18/953,861 patent/US20250353927A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504551C2 (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2020522261A5 (https=) | ||
| JP2005528914A5 (https=) | ||
| JP2022548066A5 (https=) | ||
| JP2010502183A5 (https=) | ||
| JP2021515597A5 (https=) | ||
| JP2020526478A5 (https=) | ||
| JPWO2020022475A5 (https=) | ||
| JP2007527406A5 (https=) | ||
| JP4287280B2 (ja) | ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片 | |
| JP2010536384A5 (https=) | ||
| JP2019511201A5 (https=) | ||
| JP2009517057A5 (https=) | ||
| JP2022540083A5 (https=) | ||
| JP2012504955A5 (https=) | ||
| JP2023508174A5 (https=) | ||
| JP2020516603A5 (https=) | ||
| JP2011501946A5 (https=) | ||
| JP2017507131A5 (https=) | ||
| WO2021212049A2 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| US12553893B2 (en) | Multiplex competition assay for profiling binding epitopes of affinity agents for clinical diagnostics use | |
| JP2019505166A5 (https=) | ||
| JP2023508173A5 (https=) | ||
| JP2018525320A5 (https=) | ||
| JP2025111457A5 (https=) |